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Pertussis disease remains a major global health problem. Both the public and health care professionals remain poorly informed
about the disease caused by Bordetella pertussis. Control is possible. There are now many publications highlighting important
immunization strategies to enable significant control of the mortality and morbidity caused by pertussis.
Ask family physicians about pertussis, and the likely response
will be threefold: that it is a condition of infancy or childhood,
that pertussis has been conquered by immunization, and that
diagnosis of pertussis disease is too difficult or cannot be de-
termined by laboratory diagnostics. Ask internal medicine phy-
sicians, or even respiratory physicians, and similar responses
are frequently offered. But is this perspective correct? Ask pe-
diatricians, and they will respond by saying that pertussis is a
significant problem in childhood, even though immunization
is available and has high coverage in many places, so, yes,
pertussis disease is a problem for childhood, and, no, this has
not been eliminated as a medical problem, in spite of immu-
nization. Ask infectious diseases physicians, and they will likely
respond by highlighting that pertussis disease is around, but
there is an uncertainty of incidence, because considering per-
tussis disease clinically or testing for Bordetella pertussis is not
routine. What, then, is the situation regarding pertussis disease?
There are data, there are opportunities for intervention, there
is urgent need for better understanding of this important dis-
ease, and there is urgent need for better public health policy
for pertussis disease prevention.
EPIDEMIOLOGY
From a public health perspective, pertussis disease is a problem
in developed, urbanized, apparently immunized communities,
as well as in the developing world. Globally, it is estimated that
50 million cases occur annually, 90% of which are in developing
countries, which result in 1400,000 deaths each year [1]. Many
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of these deaths are likely to be during infancy. Global reported
pertussis incidence rates (some based on clinical confirmation
only in those countries with limited access to laboratory ser-
vices), which, of course, greatly underrepresent actual cases, are
given in table 1, which shows that there is extensive disease
occurring globally.
In the prevaccine era, pertussis was a universally present
disease, with cyclic peaks every 2–5 years. Reported cases av-
eraged 157 per 100,000 persons in the United States and oc-
curred almost exclusively in unvaccinated children [2, 3]. The
early use of whole-cell vaccines and the US vaccination schedule
were highly effective and reduced the incidence of reported
pertussis to !1 case per 100,000 persons during the 1970s. Since
1984, there has been a modest increase (although some would
call it a resurgence) in the reported incidence of pertussis, to
8 cases per 100,000 persons, with cyclic peaks still occurring
at 2–5-year intervals [4, 5]. It is believed that endemic adoles-
cent and adult disease is responsible for the cyclic pattern still
seen in unvaccinated children.
Reported incidences have a range of 0.1–200 cases per
100,000 [2, 3]. Within the United States, it is estimated that
there are between 800,000 and 3.3 million cases per year [2].
A recent review of the situation in the United States [6] am-
plifies the call for the medical community to adhere to the
Advisory Committee on Immunization’s pertussis control pol-
icy. In 1990, Australia—a developed country of 20 million peo-
ple with high vaccination rates—instituted the National
Notifiable Diseases Surveillance System (NNDSS) active sur-
veillance. There were 19,815 notifications of pertussis to the
NNDSS during 1991–1996. This yields a pertussis rate of 22–
57.6 notifiable cases per 100,000 Australian population for this
period [7]. Given that this rate is for notifiable cases only, it
will be a conservative estimate; the real figure is considerably
higher (suggested “true” vs. notified cases is on the order of
3–100-fold higher). It should also be noted that 160% of no-
tifications involved persons aged 10 years [8]. In 1998, for
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Table 1. World Health Organization regional and global summaries of pertussis incidence, 1980, 1990, and 1996–2005.
Location
Year
1980 1990 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Africa 367,961 89,515 35,382 12,101 38,961 11,066 52,008 50,386 19,452 16,418 26,335 22,139
Americas 123,763 38,009 17,901 16,496 23,375 22,089 18,144 12,811 15,162 12,756 26,194 8747
Eastern Mediterranean 171,631 27,437 2823 3210 4367 2840 2112 4257 2650 1161 81,987 5164
Europe 90,546 129,735 54,745 67,307 56,317 48,897 53,675 31,084 25,176 25,530 42,220 26,425
Southeast Asia 399,310 156,028 22,479 41,940 46,666 127,76 34,930 37,813 43,250 39,371 39,002 37,764
Western Pacific 829,173 35,653 8009 25,953 15,875 17947 25,282 32,182 30,682 11,348 21,106 21,560
Global 1,982,384 476,377 141,339 167,007 185,561 115,615 186,151 168,533 13,6372 106,584 236,844 121,799
No. of countries 151 164 155 163 151 156 159 162 162 150 165 156
NOTE. Data are no. of reported cases, unless otherwise stated. Data are available at http://www.who.int/immunization_monitoring/diseases/GS_Pertussis
.pdf.
example, there were 2260 pertussis notifications for people aged
20 years. This was associated with ∼15,200 lost work days,
∼8400 general practitioner visits, and ∼4300 prescriptions [9].
Thus, pertussis is an active disease, is costly, and has much
variance globally and locally, likely due to differences in di-
agnosis, case definitions, surveillance, vaccination strategies,
and herd immunity, factors that underlie some of the confusion
about pertussis as a disease.
PERTUSSIS DISEASE IN ADULTS
AND ADOLESCENTS
Although B. pertussis infection is not generally perceived to be
as serious a problem among adolescents and adults as it is
among neonates and infants, it does represent a significant
health burden in these older age groups, including elderly per-
sons [7]. Clinical manifestations are often atypical, especially
in previously vaccinated individuals, ranging from upper re-
spiratory infection symptoms with mild cough to severe, per-
sistent cough [5]. However a significant number of adults do
have typical symptoms of paroxysmal cough, whoop, and post-
tussive vomiting, which can be severe [10]. Studies indicate
that 12%–32% of adolescents and adults with a coughing illness
lasting at least 1–2 weeks are infected with B. pertussis [10];
the percentage is dependent on which antigens were used in
the serological tests. Most adolescents and adults (80%) with
pertussis disease have a cough that lasts 21 days [11], and
many (27%) are still coughing at 90 days [10, 12].
Pertussis-related complications, some of which may be se-
rious [13], also occur fairly frequently in adolescents and adults
[14]. Although hospitalization due to pertussis disease is highest
for infants, it is not an infrequent occurrence among adoles-
cents and adults [15]. However, mortality among hospitalized
patients with pertussis is rare for those aged 110 years; in
reported cases—likely, therefore, to be more severe—it has been
cited as 0.1% [16, 17].
Although disease burden remains highest among infants aged
!1 year, the reported incidence of pertussis disease in adoles-
cents and adults is increasing in many countries [12, 18]. The
increase in pertussis among adolescents and adults may be due
to multiple factors, including waning vaccine-induced immu-
nity and increased disease recognition, diagnosis, and reporting.
Although it is not certain to what extent the change in reported
pertussis epidemiology in the postvaccination era is real, it is
clear that adolescents and adults are commonly and regularly
infected with B. pertussis and, therefore, are potentially a major
source of pediatric infection [5].
In a Swedish household study [19], 41% of adults exposed
to study children with pertussis disease showed laboratory signs
of pertussis infection; however, 44% of those adults were
asymptomatic. Older vaccinated children are also commonly
infected; nevertheless, they are less likely to have cough symp-
toms and are thus less likely to transmit B. pertussis infection
to infants.
There is widespread agreement that parents are a common
source of B. pertussis infection for infants [20, 21]. Siblings,
grandparents, aunts, and uncles are also potential sources of
infection [22, 23]. Although German data have indicated a very
similar level of antipertussis toxin and other pertussis-related
antibodies in pediatric health care workers and non–health care
workers [24], it is parents’ increased risk of coming into contact
with unprotected newborns that also makes this adult subgroup
a risk to the young [25]. One serological study reported annual
incidences of B. pertussis infection as high as 4%–16% among
health care workers [26]. Furthermore, it was shown that the
annual incidence of B. pertussis infection among physicians in
training and among emergency department staff is higher than
for any disease against which health care workers are vaccinated,
with the exception of influenza [27]. Adolescents are also an
important reservoir of infection for infants and other house-
hold members [20].
PERTUSSIS DISEASE IN INFANTS
Infants remain the group most vulnerable to B. pertussis in-
fection. During 1997–2000, in the United States, 20% of all
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Table 2. Control options.
Intervention
Purpose
ReferencesPrimary Secondary
Universal adolescent immunization Reduce pertussis incidence in adolescents;
promote herd immunity
Reduce transmission to infants [35]
Universal adult immunization Reduce pertussis incidence in adults;
promote herd immunity
Reduce transmission to others,
particularly young infants
[36, 37]
Selective immunization of
family around a newborn
Reduce transmission to infants Reduce morbidity in family [38, 34]
Selective immunization of
health care workers
Reduce transmission to patients Reduce morbidity in health care workers [39, 40]
Selective immunization of
child care workers
Reduce transmission to children Reduce morbidity in child care workers [33, 41]
Immunization of newborns at birtha Reduce pertussis disease in infants Reduce pertussis morbidity in childhood …
Immunization of mothers
during pregnancya
Reduce pertussis disease in newborns Reduce pertussis morbidity in mothers …
a Insufficient evidence of efficacy.
pertussis cases required hospitalization; 90% of patients were
infants aged !1 year [4]. Infant disease is somewhat different
from that in older children and adults. Apnea may be a key
presenting symptom, as may be pulmonary hypertension or
overwhelming multiorgan failure, with minimal respiratory
symptoms. Compared with older patients, infants are much
sicker for much longer.
Incidence rates vary widely, but the general resurgence of
pertussis is greater in the infant population than in the general
population [28]. There is also evidence that death certificates
underestimate pertussis death rates, particularly in those aged
!4 months [29]. This group is highly susceptible to pertussis,
with outbreaks occurring in neonatal intensive care units [30].
The difficulty is that infants aged !6 months are inadequately
protected, because it takes 3 doses of vaccine to provide ade-
quate protection. In most international schedules, this does not
occur until age 6 months. The conundrum for this group is
that they are not only inadequately protected but also have high
rates of exposure to older family members and health care
workers and experience the most-serious consequences of
disease.
DIAGNOSIS
Clearly, pertussis disease is poorly recognized. The classic phe-
notype of the whooping infant is well known, but adolescents
and adults with a nagging, persistent cough rarely present to
the family physician; if they do, the majority of clinicians do
not usually consider the disease to be due to B. pertussis. There
are at least 2 reasons for this: confusion over the clinical phe-
notype of pertussis disease and inconsistent and poorly stan-
dardized laboratory diagnostics.
There are at least 2 different standards for the clinical di-
agnosis of pertussis—one used in the evaluation of vaccine
efficacy and another promulgated by the World Health Orga-
nization as a clinical standard—and neither has been reinter-
preted in the context of newer diagnostics, such as PCR of
single-serum pertussis toxin IgG. The World Health Organi-
zation–recommended case definition is a case diagnosed as per-
tussis by a physician or a person with a cough lasting at least
2 weeks with at least 1 of the following symptoms: paroxysms
of coughing, inspiratory whooping, and/or posttussive vom-
iting without other apparent cause. Criteria for laboratory con-
firmation are: isolation of B. pertussis, detection of genomic
sequences by PCR, or positive paired serology.
It is likely that neither clinical standard is particularly useful
for the adult in the developed world who presents to the local
family doctor with persistent cough [4]. Therefore, newer clin-
ical criteria for such situations need to be articulated, although
perhaps the single-most-important issue is awareness—aware-
ness that pertussis is an adult disease that occurs regularly in
those previously immunized. Once the possibility is considered,
then application of an appropriate laboratory diagnostic is
recommended.
Laboratory diagnostics have come a long way since culture
on Bordet-Gengou medium. For diagnosis of acute cases in a
medical setting, where there is access to nasopharyngeal aspi-
rates or throat swabs, real-time PCR will provide rapid defin-
itive diagnosis. Standardization is, however, a problem. The
European Research Programme for Improved Pertussis Strain
Characterization and Surveillance published a consensus report
in 2005 that addressed the methodology and the application
of real-time PCR for detecting Bordetella DNA [31]. It con-
cluded that real-time PCR is more sensitive than culture for
the detection of B. pertussis and Bordetella parapertussis, es-
pecially after the first 3–4 weeks of coughing and after antibiotic
therapy has been started.
Although PCR is particularly useful in children and during
outbreak situations, there is now sufficient experience to rec-
ommend single-specimen IgG to pertussis toxin. However,
there are difficulties with standardization. A new PT reference
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serum is being developed; once this is standardized, there will
be greater reliability in this assay.
PREVENTION
Because this disease can be difficult to recognize clinically, with
variable and poorly standardized laboratory diagnostics, an-
other strategy is necessary for control; indeed, the only strategy
currently available for control of B. pertussis is immunization.
Since 2001, a multidisciplinary group of international experts
in B. pertussis and pertussis disease have met as the Global
Pertussis Initiative, to examine all the issues involving pertussis
disease. Their findings have been summarized elsewhere [32–
34]. Given all the known epidemiologic data, the Global Per-
tussis Initiative examined options for disease control. An out-
come of such deliberations was the systematic examination of
the options of universal vaccination of adults every 10 years;
universal immunization of adolescents; selective immunization
of new mothers, family, and close contacts of newborns (the
cocoon strategy); selective immunization of health care work-
ers; selective immunization of child care workers; immuniza-
tion of newborns at birth; and immunization of mothers during
pregnancy. The options for control are summarized in table 2.
Using best available evidence, the Global Pertussis Initiative
strongly endorsed the policy that regular schedules of immu-
nization against pertussis, which is available in most countries,
need to be endorsed and adhered to, with systematic and rou-
tinized delivery infrastructure and surveillance to monitor
effectiveness.
There is now sufficient evidence to recommend routine ad-
olescent immunization to boost childhood immunizations, that
targeted immunization to the close family around a newborn
be provided (the cocoon strategy), and that health care and
child care staff be immunized. There is still insufficient evidence
to recommend, at this time, immunization of the newborn at
birth or of pregnant mothers. Regarding regular (every 10 years)
vaccination of adults, there is sufficient evidence that this in-
tervention is likely to reduce the morbidity of pertussis disease
in adults. Doubts, however, remain about the overall likely
effectiveness of regular adult immunization. There is such low
awareness of pertussis in adults that it is highly unlikely that
either the medical profession or the public will, at this time,
seek regular immunization. Such lack of awareness indicates
that stronger public health policy for regular pertussis im-
munization needs to be endorsed and communicated. Given
the low awareness of pertussis among the medical community
as well as the general public, targeted campaigns to those most
at risk is at least an acceptable “patch” at this time.
CONCLUSIONS
We discussed at the beginning of this report the fact that many
medical professionals are insufficiently aware of the morbidity/
mortality of pertussis disease and of the prevention strategies
available. Certainly, pertussis immunization has drastically re-
duced disease incidence, but pertussis continues to be a serious
problem for infants and a significant cause of respiratory mor-
bidity for adolescents and adults. Greater awareness of the pub-
lic health morbidity and mortality of pertussis, thinking of
pertussis as a possible cause of coughing illness in adults, in-
tensive immunization adherence for all those in contact with
infants, and adherence to routine immunization schedules will
go a long way to reducing the burden of disease due to B.
pertussis.
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